Research programme: subcutaneous allergy immunotherapies - Allergy Therapeutics

Drug Profile

Research programme: subcutaneous allergy immunotherapies - Allergy Therapeutics

Alternative Names: Japanese cedar allergy vaccine - Allergy Therapeutics

Latest Information Update: 19 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergy Therapeutics
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Allergic rhinitis

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 19 Dec 2014 No development reported - Preclinical for Allergic rhinitis (Prevention) in United Kingdom (SC)
  • 15 Jan 2010 Preclinical development is ongoing in the United Kingdom for an SC injection-based immunotherapy against allergic rhinitis caused by Japanese cedar pollen allergen
  • 01 Feb 2007 Preclinical development is ongoing for SC injection-based immunotherapies against allergy arising from Japanese cedar pollen allergen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top